Neurogene Inc. (NGNE)

NASDAQ: NGNE · IEX Real-Time Price · USD
50.90
+1.64 (3.33%)
At close: Mar 28, 2024, 4:00 PM
49.75
-1.15 (-2.26%)
After-hours: Mar 28, 2024, 5:55 PM EDT

Company Description

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases.

The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

The company was founded in 2018 and is headquartered in New York, New York.

Neurogene Inc.
Neurogene logo
Country United States
Founded 2003
Industry Biotechnology
Sector Healthcare
Employees 91
CEO Dr. Rachel L. McMinn Ph.D.

Contact Details

Address:
535 W 24th Street, 5th Floor
New York, New York 10011
United States
Phone (877) 237-5020
Website neurogene.com

Stock Details

Ticker Symbol NGNE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001404644
Employer ID 98-0542593
SIC Code 2834

Key Executives

Name Position
Dr. Rachel L. McMinn Ph.D. Founder, Chief Executive Officer and Director
Christine Mikail Cvijic J.D. President, Chief Financial Officer and Secretary
Arvind Sreedharan Senior Vice President of Business Operations
Dr. Stuart Cobb Ph.D. Chief Scientific Officer
Donna M. Cochener-Metcalfe J.D. Senior Vice President and General Counsel
Dr. Effie Albanis M.D. Senior Vice President of Early Clinical and Translational Research
Dr. Andrew E. Mulberg CPI, FAAP, M.D. Senior Vice President of Regulatory Affairs, Quality Assurance and Quality Control
Ricardo Jimenez Senior Vice President of Technical Operations
Dr. Albena Patroneva M.B.A., M.D. Senior Vice President of Clinical Development
Dr. Julie Jordan M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 18, 2024 8-K Current Report
Mar 18, 2024 10-K Annual Report
Mar 7, 2024 144 Filing
Mar 4, 2024 144 Filing
Mar 4, 2024 8-K Current Report
Feb 21, 2024 8-K Current Report
Feb 20, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals